GlassScriptPhysician profile
Natasha Gupta
NPI 1235377789
$1,127.07
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $85.46 · 2021: $130 · 2022: $175 · 2023: $121 · 2024: $219 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $139.04 | 2020-2025 | Injectafer |
| Hologic Sales and Service, LLC | $108.55 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima, Acessa Provu System |
| Exeltis, USA INC. | $93.71 | 2021-2025 | Slynd |
| Amgen INC. | $90.17 | 2019-2025 | Evenity, Prolia |
| Coopersurgical, INC. | $83.82 | 2023-2024 | Fisherbrand Disposable Liquid Infant Heel Warmer, Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Astellas Pharma US INC | $82.20 | 2019-2024 | Veozah |
| Abbvie INC. | $59.25 | 2021-2022 | |
| Pfizer INC. | $54.13 | 2020-2024 | |
| Glaxosmithkline, LLC. | $52.29 | 2021-2025 | Shingrix, Bexsero |
| Organon LLC | $43.81 | 2024-2025 | Nexplanon |
| Aesculap, INC. | $40.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.03 | 2022-2023 | |
| Olympus America INC. | $35.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.45 | 2024 | Trintellix |
| Novo Nordisk INC | $24.24 | 2023 | Saxenda, Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $23.56 | 2019 | |
| Molnlycke Health Care US, LLC | $22.62 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $20.37 | 2024 | Exparel |
| Biohaven Pharmaceutical Holding Company LTD. | $17.23 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.63 | 2022 | |
| Mayne Pharma Commercial LLC | $13.27 | 2022 | |
| Duchesnay USA Incorporated | $12.38 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.07 | 2019 | |
| Minerva Surgical, INC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.